Thor Medical capital markets update: Enabling next-generation precision cancer treatments

Thor Medical ASA (Oslo Børs: TRMED), a leading emerging supplier of alpha-emitters for next-generation precision cancer treatment, today presents its long-term vision to transform cancer care and its strategic priorities for the coming years at a Capital Markets Update (CMU) in Stockholm.

“Thor Medical aims to become a world-leading supplier of alpha-emitters for cancer therapies and we have made significant progress towards realizing our ambitions this year. The number of clinical trials with radiopharmaceuticals for cancer treatment is at an all-time high, and successful product launches will generate high and growing demand for high-quality radioisotopes such as our Thorium-228, Radium-224, and Pb-212. Right now we are seeing the beginning of a transformative era in cancer treatment based on next-generation precision therapies,” says CEO Jasper Kurth.

Thor Medical key highlights in 2024:

• Successfully completed and commissioned pilot facilities at Herøya, on-time and on-budget and with all required authorizations secured​
• Secured strategic five-year supply agreement with ARTBIO for Thorium-228
• Shipped the first batch of Thorium-228 from the recently opened pilot facilities
• Signed three-year supply agreement with globally leading pharmaceutical company for Pb-212 for use in pre-clinical studies​
• Developed strong partnerships with feedstock suppliers to ensure consistent and reliable supply of raw materials
• Completed concept study for ‘AlphaOne’ commercial plant with an estimated capital requirement of approximately USD 30 million​

The CMU will be held at Carnegie's premises in Stockholm, Sweden, and can be followed live physically at the premises or digitally through a webcast by registering at the following link: https://tinyurl.com/2jx2hxzp

Agenda:

• Introduction – Jasper Kurth, CEO | Thor Medical
• Targeted Alpha Therapies in Cancer Treatment – Professor Jane Sosabowski, PhD | Barts Cancer Institute Queen Mary University of London
• Role of Isotope Supply for Targeted Alpha Therapies – Emanuele Ostuni, PhD, CEO | ARTBIO
• Thor Medical enabling next-generation precision cancer treatments – Jasper Kurth CEO and Brede Ellingsæter, CFO | Thor Medical

Location: Regeringsgatan 56, 111 56 Stockholm

Date & Time: 25 November 2024, 13:00-15:00 CET

It will be possible to ask questions both from the audience and via webcast during the presentations.

Contacts

• Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440, brede.ellingseter@thormedical.com

Attachments

• Download announcement as PDF.pdf
• Capital Markets Update Presentation 25 November 2024.pdf